Surgery versus stereotactic body radiotherapy for clinical stage I non-small-cell lung cancer: propensity score-matching analysis including the ratio of ground glass nodules.
Adult
Aged
Aged, 80 and over
Carcinoma, Non-Small-Cell Lung
/ mortality
Disease-Free Survival
Female
Humans
Lung Neoplasms
/ mortality
Male
Middle Aged
Multivariate Analysis
Pneumonectomy
/ methods
Postoperative Complications
/ epidemiology
Propensity Score
Radiosurgery
Retrospective Studies
Thoracic Surgery, Video-Assisted
Thoracotomy
/ methods
Treatment Outcome
Young Adult
Matched-pair analysis
Non-small-cell lung cancer
Outcome
SBRT
Thoracic surgery
Journal
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
ISSN: 1699-3055
Titre abrégé: Clin Transl Oncol
Pays: Italy
ID NLM: 101247119
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
29
04
2020
accepted:
11
07
2020
pubmed:
25
7
2020
medline:
15
9
2021
entrez:
25
7
2020
Statut:
ppublish
Résumé
To investigate whether surgery and stereotactic body radiotherapy (SBRT) yield comparable outcomes for clinical stage (c-stage) I non-small-cell lung cancer (NSCLC), propensity score-matching (PSM) analysis was conducted. This single-institutional retrospective study included patients who underwent surgery (n = 574) or SBRT (n = 182) between 2004 and 2014. PSM was performed based on tumor diameter, age, sex, performance status, forced expiratory volume, Charlson comorbidity index, and ground glass nodules (GGN) defined as cTis or cT1mi according to the 8th TNM classification. The median follow-up durations for the surgery and SBRT groups were 66 and 69 months, respectively. The multivariate analysis revealed that non-GGN was a significant factor for poorer overall survival (OS) and disease-free survival (DFS): hazard ratio (HR) 19.95% confidence interval (CI) 4.7-79, P < 0.001; and HR 28, 95% CI 6.9-110, P < 0.001, respectively. PSM identified 120 patients from each group. The 5-year OS and DFS rates of the surgery vs SBRT groups were 71% (95% CI 61-79) vs 64% (95% CI 54-72) (P = 0.41) and 63% (95% CI 53-72) vs 55% (95% CI 45-63) (P = 0.23) after PSM, respectively. The PSM analyses including the ratio of GGN demonstrated that the OS and DFS for patients with c-stage I NSCLC in the surgery group were slightly superior to those for those in the SBRT group, although both survivals were not significantly different between the two therapeutic approaches.
Identifiants
pubmed: 32705493
doi: 10.1007/s12094-020-02459-8
pii: 10.1007/s12094-020-02459-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
638-647Subventions
Organisme : Japan Society for the Promotion of Science
ID : JSPS KAKENHI 19K08183
Références
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–E386386. https://doi.org/10.1002/ijc.29210 .
doi: 10.1002/ijc.29210
pubmed: 25220842
Sawabata N, Miyaoka E, Asamura H, Nakanishi Y, Eguchi K, Mori M, et al. Japanese lung cancer registry study of 11,663 surgical cases in 2004: demographic and prognosis changes over decade. J Thorac Oncol. 2011;6(7):1229–355. https://doi.org/10.1097/JTO.0b013e318219aae2 .
doi: 10.1097/JTO.0b013e318219aae2
pubmed: 21610521
National Lung Screening Trial Research T, Church TR, Black WC, Aberle DR, Berg CD, Clingan KL, et al. Results of initial low-dose computed tomographic screening for lung cancer. N Engl J Med. 2013;368(21):1980–91. https://doi.org/10.1056/NEJMoa1209120 .
doi: 10.1056/NEJMoa1209120
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: non-small cell lung cancer V3. 2019. https://www.nccn.org/ . Accessed 14 Apr 2019.
Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010;303(11):1070–6. https://doi.org/10.1001/jama.2010.261 .
doi: 10.1001/jama.2010.261
pubmed: 20233825
pmcid: 2907644
Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF, et al. Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2012;83(1):348–53. https://doi.org/10.1016/j.ijrobp.2011.06.2003 .
doi: 10.1016/j.ijrobp.2011.06.2003
pubmed: 22104360
Nagata Y, Hiraoka M, Shibata T, Onishi H, Kokubo M, Karasawa K, et al. Prospective trial of stereotactic body radiation therapy for both operable and inoperable T1N0M0 non-small cell lung cancer: Japan clinical oncology group study JCOG0403. Int J Radiat Oncol Biol Phys. 2015;93(5):989–96. https://doi.org/10.1016/j.ijrobp.2015.07.2278 .
doi: 10.1016/j.ijrobp.2015.07.2278
pubmed: 26581137
Taremi M, Hope A, Dahele M, Pearson S, Fung S, Purdie T, et al. Stereotactic body radiotherapy for medically inoperable lung cancer: prospective, single-center study of 108 consecutive patients. Int J Radiat Oncol Biol Phys. 2012;82(2):967–73. https://doi.org/10.1016/j.ijrobp.2010.12.039 .
doi: 10.1016/j.ijrobp.2010.12.039
pubmed: 21377293
Crabtree TD, Denlinger CE, Meyers BF, El Naqa I, Zoole J, Krupnick AS, et al. Stereotactic body radiation therapy versus surgical resection for stage I non-small cell lung cancer. J Thorac Cardiovasc Surg. 2010;140(2):377–86. https://doi.org/10.1016/j.jtcvs.2009.12.054 .
doi: 10.1016/j.jtcvs.2009.12.054
pubmed: 20400121
Verstegen NE, Oosterhuis JW, Palma DA, Rodrigues G, Lagerwaard FJ, van der Elst A, et al. Stage I-II non-small-cell lung cancer treated using either stereotactic ablative radiotherapy (SABR) or lobectomy by video-assisted thoracoscopic surgery (VATS): outcomes of a propensity score-matched analysis. Ann Oncol. 2013;24(6):1543–8. https://doi.org/10.1093/annonc/mdt026 .
doi: 10.1093/annonc/mdt026
pubmed: 23425947
Palma D, Visser O, Lagerwaard FJ, Belderbos J, Slotman B, Senan S. Treatment of stage I NSCLC in elderly patients: a population-based matched-pair comparison of stereotactic radiotherapy versus surgery. Radiother Oncol. 2011;101(2):240–4. https://doi.org/10.1016/j.radonc.2011.06.029 .
doi: 10.1016/j.radonc.2011.06.029
pubmed: 21775007
Varlotto J, Fakiris A, Flickinger J, Medford-Davis L, Liss A, Shelkey J, et al. Matched-pair and propensity score comparisons of outcomes of patients with clinical stage I non-small cell lung cancer treated with resection or stereotactic radiosurgery. Cancer. 2013;119(15):2683–91. https://doi.org/10.1002/cncr.28100 .
doi: 10.1002/cncr.28100
pubmed: 23605504
Robinson CG, DeWees TA, El Naqa IM, Creach KM, Olsen JR, Crabtree TD, et al. Patterns of failure after stereotactic body radiation therapy or lobar resection for clinical stage I non-small-cell lung cancer. J Thorac Oncol. 2013;8(2):192–201. https://doi.org/10.1097/JTO.0b013e31827ce361 .
doi: 10.1097/JTO.0b013e31827ce361
pubmed: 23287852
Mokhles S, Verstegen N, Maat AP, Birim O, Bogers AJ, Mokhles MM, et al. Comparison of clinical outcome of stage I non-small cell lung cancer treated surgically or with stereotactic radiotherapy: results from propensity score analysis. Lung Cancer. 2015;87(3):283–9. https://doi.org/10.1016/j.lungcan.2015.01.005 .
doi: 10.1016/j.lungcan.2015.01.005
pubmed: 25622781
Matsuo Y, Chen F, Hamaji M, Kawaguchi A, Ueki N, Nagata Y, et al. Comparison of long-term survival outcomes between stereotactic body radiotherapy and sublobar resection for stage I non-small-cell lung cancer in patients at high risk for lobectomy: a propensity score matching analysis. Eur J Cancer. 2014;50(17):2932–8. https://doi.org/10.1016/j.ejca.2014.09.006 .
doi: 10.1016/j.ejca.2014.09.006
pubmed: 25281527
Port JL, Parashar B, Osakwe N, Nasar A, Lee PC, Paul S, et al. A propensity-matched analysis of wedge resection and stereotactic body radiotherapy for early stage lung cancer. Ann Thorac Surg. 2014;98(4):1152–9. https://doi.org/10.1016/j.athoracsur.2014.04.128 .
doi: 10.1016/j.athoracsur.2014.04.128
pubmed: 25085557
Rosen JE, Salazar MC, Wang Z, Yu JB, Decker RH, Kim AW, et al. Lobectomy versus stereotactic body radiotherapy in healthy patients with stage I lung cancer. J Thorac Cardiovasc Surg. 2016;152(1):44–54 e9. https://doi.org/10.1016/j.jtcvs.2016.03.060 .
doi: 10.1016/j.jtcvs.2016.03.060
pubmed: 27131846
Hashizume T, Yamada K, Okamoto N, Saito H, Oshita F, Kato Y, et al. Prognostic significance of thin-section CT scan findings in small-sized lung adenocarcinoma. Chest. 2008;133(2):441–7. https://doi.org/10.1378/chest.07-1533 .
doi: 10.1378/chest.07-1533
pubmed: 18071015
Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11(1):39–51. https://doi.org/10.1016/j.jtho.2015.09.009 .
doi: 10.1016/j.jtho.2015.09.009
pubmed: 26762738
Maeshima AM, Tochigi N, Yoshida A, Asamura H, Tsuta K, Tsuda H. Histological scoring for small lung adenocarcinomas 2 cm or less in diameter: a reliable prognostic indicator. J Thorac Oncol. 2010;5(3):333–9. https://doi.org/10.1097/JTO.0b013e3181c8cb95 .
doi: 10.1097/JTO.0b013e3181c8cb95
pubmed: 20125041
Yim J, Zhu LC, Chiriboga L, Watson HN, Goldberg JD, Moreira AL. Histologic features are important prognostic indicators in early stages lung adenocarcinomas. Mod Pathol. 2007;20(2):233–41. https://doi.org/10.1038/modpathol.3800734 .
doi: 10.1038/modpathol.3800734
pubmed: 17192789
Chang JY, Senan S, Paul MA, Mehran RJ, Louie AV, Balter P, et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol. 2015;16(6):630–7. https://doi.org/10.1016/S1470-2045(15)70168-3 .
doi: 10.1016/S1470-2045(15)70168-3
pubmed: 25981812
pmcid: 4489408
Shibamoto Y, Hashizume C, Baba F, Ayakawa S, Miyakawa A, Murai T, et al. Stereotactic body radiotherapy using a radiobiology-based regimen for stage I non-small-cell lung cancer: five-year mature results. J Thorac Oncol. 2015;10(6):960–4. https://doi.org/10.1097/JTO.0000000000000525 .
doi: 10.1097/JTO.0000000000000525
pubmed: 26001145
Travis WD, Asamura H, Bankier AA, Beasley MB, Detterbeck F, Flieder DB, et al. The IASLC lung cancer staging project: proposals for coding T categories for subsolid nodules and assessment of tumor size in part-solid tumors in the forthcoming eighth edition of the TNM classification of lung cancer. J Thorac Oncol. 2016;11(8):1204–23. https://doi.org/10.1016/j.jtho.2016.03.025 .
doi: 10.1016/j.jtho.2016.03.025
pubmed: 27107787
Oda R, Okuda K, Osaga S, Watanabe T, Sakane T, Tatematsu T, et al. Long-term outcomes of video-assisted thoracoscopic surgery lobectomy vs. thoracotomy lobectomy for stage IA non-small cell lung cancer. Surg Today. 2019;49(5):369–77. https://doi.org/10.1007/s00595-018-1746-4 .
doi: 10.1007/s00595-018-1746-4
pubmed: 30511319
Shibamoto Y, Miyakawa A, Otsuka S, Iwata H. Radiobiology of hypofractionated stereotactic radiotherapy: what are the optimal fractionation schedules? J Radiat Res. 2016;57(Suppl 1):i76–i82. https://doi.org/10.1093/jrr/rrw015 .
doi: 10.1093/jrr/rrw015
pubmed: 27006380
pmcid: 4990108
Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676–82. https://doi.org/10.1093/aje/kwq433 .
doi: 10.1093/aje/kwq433
Yao XI, Wang X, Speicher PJ, Hwang ES, Cheng P, Harpole DH, et al. Reporting and guidelines in propensity score analysis: a systematic review of cancer and cancer surgical studies. J Natl Cancer Inst. 2017;109:8. https://doi.org/10.1093/jnci/djw323 .
doi: 10.1093/jnci/djw323
Kinoshita FL, Ito Y, Morishima T, Miyashiro I, Nakayama T. Sex differences in lung cancer survival: long-term trends using population-based cancer registry data in Osaka. Japan Jpn J Clin Oncol. 2017;47(9):863–9. https://doi.org/10.1093/jjco/hyx094 .
doi: 10.1093/jjco/hyx094
pubmed: 28903532
Sakurai H, Asamura H, Goya T, et al. Survival differences by gender for resected non-small cell lung cancer: a retrospective analysis of 12,509 cases in a Japanese Lung Cancer Registry study. J Thorac Oncol. 2010;5(10):1594–601. https://doi.org/10.1097/JTO.0b013e3181f1923b .
doi: 10.1097/JTO.0b013e3181f1923b
pubmed: 20736855
Katz MS, Husain ZA. Stereotactic radiotherapy or surgery for early-stage non-small-cell lung cancer. Lancet Oncol. 2016;17(2):e41–e4242. https://doi.org/10.1016/S1470-2045(16)00026-7 .
doi: 10.1016/S1470-2045(16)00026-7
pubmed: 26868347
Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg. 1995;60(3):615–22. https://doi.org/10.1016/0003-4975(95)00537-u (discussion 22-3).
doi: 10.1016/0003-4975(95)00537-u
pubmed: 7677489